228 related articles for article (PubMed ID: 23783137)
1. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group.
Levy Hara G; Gould I; Endimiani A; Pardo PR; Daikos G; Hsueh PR; Mehtar S; Petrikkos G; Casellas JM; Daciuk L; Paciel D; Novelli A; Saginur R; Pryluka D; Medina J; Savio E
J Chemother; 2013 Jun; 25(3):129-40. PubMed ID: 23783137
[TBL] [Abstract][Full Text] [Related]
2. A pediatric case of New Delhi metallo-β-lactamase-1-producing Enterobacteriaceae in the United States.
Green DA; Srinivas N; Watz N; Tenover FC; Amieva M; Banaei N
Pediatr Infect Dis J; 2013 Nov; 32(11):1291-4. PubMed ID: 23743543
[TBL] [Abstract][Full Text] [Related]
3. Options for treating carbapenem-resistant Enterobacteriaceae.
Rafailidis PI; Falagas ME
Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
[TBL] [Abstract][Full Text] [Related]
4. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
Tängdén T; Giske CG
J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628
[TBL] [Abstract][Full Text] [Related]
5. Over-treatment of carbapenemase-producing Enterobacteriaceae.
Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline.
Choudhury S; Yeng JL; Krishnan PU
Clin Microbiol Infect; 2015 Oct; 21(10):e75-6. PubMed ID: 26086572
[No Abstract] [Full Text] [Related]
7. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
Cantón R; Canut A; Morosini MI; Oliver A
Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
[TBL] [Abstract][Full Text] [Related]
8. The management of multidrug-resistant Enterobacteriaceae.
Bassetti M; Peghin M; Pecori D
Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.
Nabarro LE; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2015 Dec; 34(12):2307-11. PubMed ID: 26363636
[TBL] [Abstract][Full Text] [Related]
10. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
11. The challenges of carbapenemase-producing Enterobacteriaceae and infection prevention: protecting patients in the chaos.
Savard P; Carroll KC; Wilson LE; Perl TM
Infect Control Hosp Epidemiol; 2013 Jul; 34(7):730-9. PubMed ID: 23739078
[No Abstract] [Full Text] [Related]
12. [Therapeutic options for carbapenemase-producing Enterobacteriaceae].
Salgado P; Gilsanz F; Maseda E
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():12-5. PubMed ID: 26365727
[TBL] [Abstract][Full Text] [Related]
13. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
14. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
Berçot B; Poirel L; Dortet L; Nordmann P
J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y;
J Antimicrob Chemother; 2013 Aug; 68(8):1832-7. PubMed ID: 23557926
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.
Falagas ME; Karageorgopoulos DE; Nordmann P
Future Microbiol; 2011 Jun; 6(6):653-66. PubMed ID: 21707312
[TBL] [Abstract][Full Text] [Related]
18. Control strategies for carbapenemase-producing Enterobacteriaceae at different levels of the healthcare system.
Asensio Á; Cantero M; Shaw E; Vergara-López S
Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():61-6. PubMed ID: 25542054
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of invasive carbapenemase-producing Enterobacteriaceae infections in children using carbapenem-aminoglycoside combination therapy: A case series.
Williams PCM; Bartlett AW; Palasanthiran P; Armstrong B; McMullan BJ
Infect Dis Health; 2020 Nov; 25(4):314-318. PubMed ID: 32698988
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
